Alnylam Pharmaceuticals Inc
XMUN:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XMUN:DUL
|
US |
|
M
|
Mit SIM SpA
MIL:MTS
|
IT |
|
C
|
Continental AG
XMUN:CON
|
DE |
|
K
|
Kingspan Group PLC
F:KRX
|
IE |
|
C
|
Carter's Inc
XMUN:HCH
|
US |
|
F
|
FirstEnergy Corp
XMUN:FE7
|
US |
|
Sibanye Stillwater Ltd
F:47VS
|
ZA |
|
CNB Financial Corp
NASDAQ:CCNE
|
US |
|
C
|
Commercial Metals Co
SWB:CMS
|
US |
|
L
|
Lowe's Companies Inc
XMUN:LWE
|
US |
|
E
|
Eni SpA
XMUN:ENI
|
IT |
|
Barratt Developments P L C
LSE:BDEV
|
UK |
|
A
|
Axon Enterprise Inc
XMUN:TCS
|
US |
|
Grupo Aeroportuario del Sureste SAB de CV
F:AEDA
|
MX |
|
C
|
Chorus Ltd
F:7CH
|
NZ |
|
I
|
Impianti SpA
F:F67
|
IT |
|
A
|
Avis Budget Group Inc
SWB:CUCA
|
US |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 391.59 EUR with a low forecast of 205.44 EUR and a high forecast of 512.23 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
391.59
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 391.59 EUR with a low forecast of 205.44 EUR and a high forecast of 512.23 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
34%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 3 years is 34%.
What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
31%
The compound annual growth rate for Gross Profit over the next 3 years is 31%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
72%
The compound annual growth rate for Operating Income over the next 3 years is 72%.
What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
93%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 93%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
87%
The compound annual growth rate for Net Income over the next 3 years is 87%.
